

Adaptive Radiotherapy ***The Next Frontier*** ***in Radiation Medicine***

Michael Milosevic

Radiation Medicine Program
Princess Margaret Hospital and
University of Toronto
Toronto, Canada



Radiation Oncology
UNIVERSITY OF TORONTO



Princess Margaret Hospital

Radiotherapy in the 21st Century: *Individualized Treatment*







Image-guided adaptive RT




Biology and molecular targeting

**Synergistic strategies for improving tumor control
and reducing side effects**


The Evolution of Radiotherapy for Cancer



1980's: 60 Gy




1990's: 70 Gy




2000's: 80 Gy

High Precision Radiotherapy



**Linear accelerator
with integrated CT imaging**



**Treat the tumor and
avoid normal organs**

Image-guided IMRT to \uparrow tumor control and/or \downarrow toxicity


Tumors Change

- Tumors are spatially heterogeneous
- Tumors are unstable
- Position changes
 - Inter-fraction, Intra-fraction
- Size and shape changes
- Biology changes




Liver metastasis


The Evolution of Adaptive RT



Adapt to Changing Conditions




Cervix Cancer



Diagnosis

Cervix Cancer





Diagnosis



Mid-treatment

50 Gy

IMRT for Cervix Cancer



IMRT for Cervix Cancer *Challenges*

- Tumor and LN identification
 - Gross, microscopic, observer agreement
- Complex target volumes
- Tumor and normal tissue motion
- Tumor regression and deformation
- Clinical response to a shrinking target
- Online daily image quality
- Workload (contouring, planning, quality)

Cervix Cancer

Motion, Regression, Deformation

INTER- AND INTRAFRACTIONAL TUMOR AND ORGAN MOVEMENT IN PATIENTS WITH CERVICAL CANCER UNDERGOING RADIOTHERAPY: A CINEMATIC-MRI POINT-OF-INTEREST STUDY

PHILIP CHAN, M.B.B.S.,^{*†‡} ROBERT DINNIWELL, M.D.,^{*†‡} MASOOM A. HAIDER, M.D.,^{§¶} YOUNG-BIN CHO, PH.D.,^{*†} DAVID JAFFRAY, PH.D.,^{*†} GINA LOCKWOOD, M.MATH.,^{||} WILFRED LEVIN, M.B.,^{*†} LEE MANCHUL, M.D.,^{*†} ANTHONY FYLES, M.D.,^{*†‡} AND MICHAEL MILOSEVIC, M.D.^{*†‡}

^{*}Radiation Medicine Program, [§]Department of Medical Imaging, and ^{||}Clinical Study Coordination and Biostatistics, Princess Margaret Hospital/Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; Departments of [†]Radiation Oncology and [¶]Medical Imaging, and [‡]Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada

CERVICAL CANCER REGRESSION MEASURED USING WEEKLY MAGNETIC RESONANCE IMAGING DURING FRACTIONATED RADIOTHERAPY: RADIOBIOLOGIC MODELING AND CORRELATION WITH TUMOR HYPOXIA

KAREN LIM, M.B.B.S.,^{*†} PHILIP CHAN, M.B.B.S.,^{*} ROBERT DINNIWELL, M.D.,^{*†} ANTHONY FYLES, M.D.,^{*†} MASOOM HAIDER, M.D.,^{‡§} YOUNG-BIN CHO, PH.D.,^{*||} DAVID JAFFRAY, PH.D.,^{*†} LEE MANCHUL, M.D.,^{*†} WILFRED LEVIN, M.D.,^{*†} RICHARD P. HILL, PH.D.,^{†||¶} AND MICHAEL MILOSEVIC, M.D.^{*†}

^{*}Radiation Medicine Program, [‡]Department of Medical Imaging, and ^{||}Division of Applied Molecular Oncology, Princess Margaret Hospital/Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; Departments of [†]Radiation Oncology, [§]Medical Imaging, and [¶]Medical Biophysics, University of Toronto, Toronto, ON, Canada

Motion and deformation of the target volumes during IMRT for cervical cancer: What margins do we need?

Linda van de Bunt^{a,*}, Ina M. Jürgenliemk-Schulz^a, Gérard A.P. de Kort^b, Judith M. Roesink^a, Robbert J.H.A. Tersteeg^a, Uulke A. van der Heide^a

^aDepartment of Radiation Oncology, and ^bDepartment of Radiology, University Medical Center Utrecht, The Netherlands

An assessment of interfractional uterine and cervical motion: Implications for radiotherapy target volume definition in gynaecological cancer[☆]

Alexandra Taylor^{*}, Melanie E.B. Powell


Department of Radiotherapy, St. Bartholomew's Hospital, London, UK

CERVIX REGRESSION AND MOTION DURING THE COURSE OF EXTERNAL BEAM CHEMORADIATION FOR CERVICAL CANCER

BETH M. BEADLE, M.D., PH.D.,^{*} ANUJA JHINGRAN, M.D.,^{*} MOHAMMAD SALEHPOUR, PH.D.,[†] MARIANNE SAM, B.S.,^{*} REVATHY B. IYER, M.D.,[‡] AND PATRICIA J. EIFEL, M.D.^{*}


Departments of ^{*}Radiation Oncology, [†]Radiation Physics, and [‡]Diagnostic Imaging, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Cervix Cancer: Change During RT



Weekly MR imaging to track tumor movement


Tumor Regression During RT



Cervix Motion During RT




Cervix (Week 1)



Point-of-Interest (POI) Analysis

Uterine PTV Margins for IMRT



Cervix Cancer Motion *Summary*

- Complex, spatially-dependent motion
- Large inter-fraction tumor motion
- Small intra-fraction tumor motion
- Tumor regression and deformation


Cervix Cancer Motion *Summary*

- Complex, spatially-dependent motion
- Large inter-fraction tumor motion
- Small intra-fraction tumor motion
- Tumor regression and deformation
- How do these changes during treatment influence the dose delivered to the tumor and critical normal tissues?

Cervix Cancer Motion







Dosimetric Impact of Margin Size

- 20 patients, weekly MR's
- 3 plans (50 Gy):
 - (a) Conventional
 - (b) 20 mm PTV
 - (c) 5 mm PTV
- “Delivered” dose accumulation over the course of treatment



Courtesy of Karen Lim


Deformable Soft Tissue Modeling




MORPHEUS:
Mapping of weekly
anatomy to planning
geometry

Delivered Dose Accumulation

Dose-Difference Map




ORBIT: Mapping of delivered vs. planned dose to tumor and normal organs




Cervix Cancer Motion and Dose


Case 1



2 weeks



Case 2




4 weeks




Cervix Cancer Motion

Dosimetric Impact of Margin Size




Cervix Cancer Motion

Dosimetric Impact of Margin Size




Tumor coverage



Normal organ sparing

Cervix Cancer Motion




Extreme, complex and unpredictable motion implies the need for:


- **Daily image guidance**
- **Daily “adaptive” re-planning**

Cervix Cancer Adaptive RT



1) IMRT with uniform 3mm PTV margin, no replanning



2) Automatic replan with pre-treatment optimization function



Cervix Cancer Adaptive RT



Summary

- Tumors move, shrink and change shape.
- Extreme, unpredictable anatomic changes can occur.
- Large safety margins are required to account for inter- and intra-fraction movement and avoid missing tumor.
- Smaller margins may be feasible with daily online imaging and adaptive replanning, allowing dose escalation and/or normal tissue sparing.
- Opportunities for research and development
 - Daily online image quality, automated contouring, automated replanning, quality assurance, biologic adaptation

OCAIRO

Ontario Consortium for Adaptive Interventions in Radiation Oncology

- Alliance of 7 Ontario institutions
- Inter-disciplinary
- Funding from Ontario Research Fund
- Research Themes:
 - 3D/4D imaging for adaptive RT
 - Adaptive RT processes
 - Validation of imaging, deformation and dose accumulation techniques
 - Software development for clinical translation



Princess Margaret Hospital

Radiation Oncology: A. Fyles, W. Levin, L. Manchul, K. Lim, P. Chan

Medical Physics: Y-B Cho, K. Brock, D. Jaffray, J. Jezioranski, I. Yeung,
T. Craig, J. Stewart, J. Moseley, M. Sharpe, J. Xie

Medical Imaging: M. Haider

Radiotherapy: V. Kelly, J. Paterson

Biostatistics: M. Pintilie, G. Lockwood

RaySearch Laboratories AB

A. Lundin, H. Rehbinder, J. Löf

Supported by:

Canadian Cancer Society

Terry Fox Foundation

Giovanni and Concetta Guglietti Family Trust